Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.61, $0.06 better than the analyst estimate of $0.55. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.06 billion.

GUIDANCE:

Teva Pharma sees FY2024 EPS of $2.30-$2.50, versus the consensus of $2.46. Teva Pharma sees FY2024 revenue of $16-16.4 billion, versus the consensus of $15.994 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.